Sodium-Glucose Cotransporter 2 Inhibitors in Patients with Diabetes and Coronary Artery Disease: Translating the Benefits of the Molecular Mechanisms of Gliflozins into Clinical Practice.
CAD
GUTI
SGLT2 inhibitors (SGLT2i)
adverse event
type 2 diabetes mellitus (T2DM)
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
30 Apr 2023
30 Apr 2023
Historique:
received:
01
02
2023
revised:
25
04
2023
accepted:
27
04
2023
medline:
15
5
2023
pubmed:
13
5
2023
entrez:
13
5
2023
Statut:
epublish
Résumé
Sodium-glucose cotransporter 2 inhibitors (SGLT2i) were initially developed for the treatment of diabetes due to their antihyperglycemic activity. However, in the light of the most recent clinical studies, they are revolutionizing the approach to cardiovascular disease in patients with and without diabetes. We aimed to generate real-world data about the use of SGLT2i in patients with T2DM and coronary artery disease (CAD), focusing on their effectiveness in glycemic control, adherence, long-term efficacy, and safety outcomes. On the basis of the inclusion and exclusion criteria, 143 patients were enrolled. Patients were treated with canagliflozin (
Identifiants
pubmed: 37175805
pii: ijms24098099
doi: 10.3390/ijms24098099
pmc: PMC10179032
pii:
doi:
Substances chimiques
Sodium-Glucose Transporter 2 Inhibitors
0
Glycated Hemoglobin
0
Hypoglycemic Agents
0
Glucose
IY9XDZ35W2
Sodium
9NEZ333N27
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Références
Acta Diabetol. 2020 Mar;57(3):367-375
pubmed: 31673896
Diabetes Obes Metab. 2019 Feb;21(2):434-438
pubmed: 30207042
Eur Heart J. 2020 Jan 7;41(2):255-323
pubmed: 31497854
Postgrad Med. 2016 May;128(4):409-17
pubmed: 26982554
Nutr Metab Cardiovasc Dis. 2022 May;32(5):1195-1201
pubmed: 35260306
N Engl J Med. 2017 Aug 17;377(7):644-657
pubmed: 28605608
BMJ Open. 2016 Nov 9;6(11):e013166
pubmed: 28186945
N Engl J Med. 2015 Nov 26;373(22):2117-28
pubmed: 26378978
Diab Vasc Dis Res. 2015 Mar;12(2):78-89
pubmed: 25616707
Diabetes Care. 2021 Jan;44(Suppl 1):S125-S150
pubmed: 33298421
Ann Intern Med. 2013 Aug 20;159(4):262-74
pubmed: 24026259
Diabetes Obes Metab. 2016 Aug;18(8):783-94
pubmed: 27059700
Nutr Metab Cardiovasc Dis. 2016 Nov;26(11):963-970
pubmed: 27514605
Circulation. 2022 May 3;145(18):e895-e1032
pubmed: 35363499
Clin Med Insights Endocrinol Diabetes. 2022 Feb 14;15:11795514221074663
pubmed: 35185350
Can J Diabetes. 2020 Feb;44(1):93-102
pubmed: 31882322
Diabetes Obes Metab. 2014 Feb;16(2):159-69
pubmed: 23906445
N Engl J Med. 2019 Jan 24;380(4):347-357
pubmed: 30415602
Diabetes Care. 2022 Mar 1;45(3):604-613
pubmed: 35043165
N Engl J Med. 2020 Oct 8;383(15):1413-1424
pubmed: 32865377
PLoS One. 2016 Nov 11;11(11):e0166125
pubmed: 27835680
Diabetes Obes Metab. 2011 Oct;13(10):928-38
pubmed: 21672123
Diabetes Care. 2012 Jul;35(7):1473-8
pubmed: 22446170
Diabetes Obes Metab. 2014 Feb;16(2):124-36
pubmed: 23911013
Int J Mol Sci. 2021 May 30;22(11):
pubmed: 34070765
Eur Heart J. 2021 Sep 21;42(36):3599-3726
pubmed: 34447992
N Engl J Med. 2020 Oct 8;383(15):1425-1435
pubmed: 32966714
N Engl J Med. 2019 Nov 21;381(21):1995-2008
pubmed: 31535829
Eur Heart J. 2007 Oct;28(20):2525-38
pubmed: 17951287
J Am Coll Cardiol. 2021 Jan 26;77(3):243-255
pubmed: 33197559
Diabetes Metab Res Rev. 2021 Jan;37(1):e3350
pubmed: 32447808